Basic Information
RNALocate ID: | RLID:01001764 |
RNA Symbol: | hsa-miR-130a-3p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-130a |
RNA ID: | miRBase:MIMAT0000425 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21695135 |
Tissue/Cell Line: | Cell line (HeLa) |
Method: | Microarray |
Heatmap showing the 57 miRNAs differentially expressed in HeLa cells from mitochondrial and cytosolic RNA. Three independent microarray profiling experiments (microarray n1, n2 and n3) are shown and reproducibly revealed 13 miRNAs enriched in mitochondrial RNA. Originally published in PLoS One. Bandiera S, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | While 44 miRNAs showed a greater enrichment in the cytosolic Hy3-labeled RNA fraction, 13 miRNAs were significantly and reproducibly enriched in the mitochondrial Hy5-labeled RNA sample (ranging from 1.5- to 56-fold), namely hsa-miR-1973, hsa-miR-1275, hsa-miR-494, hsa-miR-513a-5p, hsa-miR-1246, hsa-miR-328, hsa-miR-1908, hsa-miR-1972, hsa-miR-1974, hsa-miR-1977, hsa-miR-638, hsa-miR-1978 and hsa-miR-1201 (Figure 5A). Data are collected from Figure 5. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001763 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001765 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001766 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001767 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001768 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001769 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11001726 | Exosome | Serum | 29143228 |
RLID:11001727 | Exosome | Primary dendritic cells | 21505438 |
RLID:11001728 | Exosome | Breast milk | 22211110 |
RLID:11001729 | Exosome | Brain tissue | 23382797 |
RLID:11001730 | Exosome | Plasma | 23663360 |
RLID:11001731 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
RLID:11001732 | Microvesicle | Plasma | 23077538 |
RLID:11001733 | Microvesicle | Seminal plasma | 23539611 |
RLID:11001734 | Microvesicle | Follicular fluid | 23666971 |
RLID:11001735 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000078 | Exosome | Blood|Endothelial cells | |
RLID-D:11000353 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-130a-3p | Splenic marginal zone lymphoma | MNDR-E-MI-10672 |
MNDR | hsa-miR-130a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-10673 |
MNDR | hsa-miR-130a-3p | Peripheral artery disease | MNDR-E-MI-10674 |
MNDR | hsa-miR-130a-3p | Oral squamous cell carcinoma | MNDR-E-MI-10675 |
MNDR | hsa-miR-130a-3p | Medulloblastoma | MNDR-E-MI-10676 |
MNDR | hsa-miR-130a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-10677 |
MNDR | hsa-miR-130a-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-10678 |
MNDR | hsa-miR-130a-3p | Spinocerebellar ataxia type 1 | MNDR-E-MI-10679 |
MNDR | hsa-miR-130a-3p | Lymphoma | MNDR-E-MI-10680 |
MNDR | hsa-miR-130a-3p | Lymphoma non-hodgkin | MNDR-E-MI-10681 |
MNDR | hsa-miR-130a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-10682 |
MNDR | hsa-miR-130a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-10683 |
MNDR | hsa-miR-130a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-10684 |
MNDR | hsa-miR-130a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-10685 |
MNDR | hsa-miR-130a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-10686 |
MNDR | hsa-miR-130a-3p | Breast cancer luminal | MNDR-E-MI-10687 |
MNDR | hsa-miR-130a-3p | Myeloid neoplasm | MNDR-E-MI-10688 |
MNDR | hsa-miR-130a-3p | Niemann-pick disease type c | MNDR-E-MI-10689 |
MNDR | hsa-miR-130a-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-10690 |
MNDR | hsa-miR-130a-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-10691 |
MNDR | hsa-miR-130a-3p | Autosomal recessive limb-girdle muscular dystrophy type 2a | MNDR-E-MI-10692 |
MNDR | hsa-miR-130a-3p | Dermatomyositis | MNDR-E-MI-10693 |
MNDR | hsa-miR-130a-3p | Prostate cancer | MNDR-E-MI-10694 |
MNDR | hsa-miR-130a-3p | Prostate carcinoma | MNDR-E-MI-10695 |
MNDR | hsa-miR-130a-3p | Chronic lymphocytic leukemia | MNDR-E-MI-10696 |
MNDR | hsa-miR-130a-3p | Gastric cancer | MNDR-E-MI-10697 |
MNDR | hsa-miR-130a-3p | Gastric lymphoma | MNDR-E-MI-10698 |
MNDR | hsa-miR-130a-3p | Alzheimer disease | MNDR-E-MI-10699 |
MNDR | hsa-miR-130a-3p | Attention deficit hyperactivity disorder | MNDR-E-MI-10700 |
MNDR | hsa-miR-130a-3p | Intracranial aneurysm | MNDR-E-MI-10701 |
MNDR | hsa-miR-130a-3p | Bladder cancer | MNDR-E-MI-10702 |
MNDR | hsa-miR-130a-3p | Dysautonomia familial | MNDR-E-MI-10703 |
MNDR | hsa-miR-130a-3p | Muscular dystrophy duchenne | MNDR-E-MI-10704 |
MNDR | hsa-miR-130a-3p | Seizures | MNDR-E-MI-10705 |
MNDR | hsa-miR-130a-3p | Head and neck cancer | MNDR-E-MI-10706 |
MNDR | hsa-miR-130a-3p | Leukemia | MNDR-E-MI-10707 |
MNDR | hsa-miR-130a-3p | Friedreich ataxia | MNDR-E-MI-10708 |
MNDR | hsa-miR-130a-3p | Huntington disease | MNDR-E-MI-10709 |
MNDR | hsa-miR-130a-3p | Cardiovascular disease | MNDR-E-MI-10710 |
MNDR | hsa-miR-130a-3p | Carotid stenosis | MNDR-E-MI-10711 |
MNDR | hsa-miR-130a-3p | Moyamoya disease | MNDR-E-MI-10712 |
MNDR | hsa-miR-130a-3p | Lung cancer | MNDR-E-MI-10713 |
MNDR | hsa-miR-130a-3p | Parkinson disease | MNDR-E-MI-10714 |
MNDR | hsa-miR-130a-3p | Niemann-pick disease | MNDR-E-MI-10715 |
MNDR | hsa-miR-130a-3p | Basal-like breast cancer | MNDR-E-MI-10716 |
MNDR | hsa-miR-130a-3p | Neuroendocrine neoplasia | MNDR-E-MI-10717 |
MNDR | hsa-miR-130a-3p | Thyroid cancer | MNDR-E-MI-10718 |
MNDR | hsa-miR-130a-3p | Pancreatic cancer | MNDR-E-MI-10719 |
MNDR | hsa-miR-130a-3p | Rectum adenocarcinoma | MNDR-E-MI-10720 |
MNDR | hsa-miR-130a-3p | Nephroblastoma | MNDR-E-MI-10721 |
MNDR | hsa-miR-130a-3p | Colon cancer | MNDR-E-MI-10722 |
MNDR | hsa-miR-130a-3p | Ischemic attack transient | MNDR-E-MI-10723 |
MNDR | hsa-miR-130a-3p | Colon adenocarcinoma | MNDR-E-MI-10724 |
MNDR | hsa-miR-130a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-10725 |
MNDR | hsa-miR-130a-3p | Ovarian cancer | MNDR-E-MI-10726 |
MNDR | hsa-miR-130a-3p | Prostate adenocarcinoma | MNDR-E-MI-10727 |
MNDR | hsa-miR-130a-3p | Infantile hemangioma | MNDR-E-MI-10728 |
MNDR | hsa-miR-130a-3p | Carcinoma ductal breast | MNDR-E-MI-10729 |
MNDR | hsa-miR-130a-3p | Invasive ductal carcinoma | MNDR-E-MI-10730 |
MNDR | hsa-miR-130a-3p | Glioblastoma | MNDR-E-MI-10731 |
MNDR | hsa-miR-130a-3p | Astrocytoma | MNDR-E-MI-10732 |
MNDR | hsa-miR-130a-3p | Glioma | MNDR-E-MI-10733 |
MNDR | hsa-miR-130a-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-10734 |
MNDR | hsa-miR-130a-3p | Nemaline myopathy | MNDR-E-MI-10735 |
MNDR | hsa-miR-130a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-10736 |
MNDR | hsa-miR-130a-3p | Temporal lobe epilepsy | MNDR-E-MI-10737 |
MNDR | hsa-miR-130a-3p | Osteosarcoma | MNDR-E-MI-10738 |
MNDR | hsa-miR-130a-3p | Coronary artery disease | MNDR-E-MI-10739 |
MNDR | hsa-miR-130a-3p | Meningioma | MNDR-E-MI-10740 |
MNDR | hsa-miR-130a-3p | Liver cancer | MNDR-E-MI-10741 |
MNDR | hsa-miR-130a-3p | Uterine cancer | MNDR-E-MI-10742 |
MNDR | hsa-miR-130a-3p | Gastric adenocarcinoma | MNDR-E-MI-10743 |
MNDR | hsa-miR-130a-3p | Lung squamous cell carcinoma | MNDR-E-MI-10744 |
MNDR | hsa-miR-130a-3p | Carcinoma lung non-small-cell | MNDR-E-MI-10745 |
MNDR | hsa-miR-130a-3p | Lung adenocarcinoma | MNDR-E-MI-10746 |
MNDR | hsa-miR-130a-3p | Thyroid carcinoma | MNDR-E-MI-10747 |
MNDR | hsa-miR-130a-3p | Bladder urothelial carcinoma | MNDR-E-MI-10748 |
MNDR | hsa-miR-130a-3p | Brain stem cancer | MNDR-E-MI-10749 |
MNDR | hsa-miR-130a-3p | Cervical cancer | MNDR-E-MI-10750 |
MNDR | hsa-miR-130a-3p | Carcinoma renal cell | MNDR-E-MI-10751 |
MNDR | hsa-miR-130a-3p | Clear cell renal cell carcinoma | MNDR-E-MI-10752 |
MNDR | hsa-miR-130a-3p | Adenocarcinoma clear cell | MNDR-E-MI-10753 |
MNDR | hsa-miR-130a-3p | Chromophobe renal cell carcinoma | MNDR-E-MI-10754 |
MNDR | hsa-miR-130a-3p | Brain edema | MNDR-E-MI-10755 |
MNDR | hsa-miR-130a-3p | Cholangiocarcinoma | MNDR-E-MI-10756 |
MNDR | hsa-miR-130a-3p | Esophageal cancer | MNDR-E-MI-10757 |
MNDR | hsa-miR-130a-3p | Lung small cell carcinoma | MNDR-E-MI-10758 |
MNDR | hsa-miR-130a-3p | Synovial sarcoma | MNDR-E-MI-10759 |
MNDR | hsa-miR-130a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-10760 |
MNDR | hsa-miR-130a-3p | T acute lymphoblastic leukemia | MNDR-E-MI-10761 |
MNDR | hsa-miR-130a-3p | Acute t cell leukemia | MNDR-E-MI-10762 |
MNDR | hsa-miR-130a-3p | Fibromyalgia | MNDR-E-MI-10763 |
MNDR | hsa-miR-130a-3p | Breast invasive carcinoma | MNDR-E-MI-10764 |
MNDR | hsa-miR-130a-3p | Hepatocellular carcinoma | MNDR-E-MI-10765 |
MNDR | hsa-miR-130a-3p | B-cell lymphoma | MNDR-E-MI-10766 |
MNDR | hsa-miR-130a-3p | Rheumatoid arthritis | MNDR-E-MI-10767 |
MNDR | hsa-miR-130a-3p | Hodgkin lymphoma | MNDR-E-MI-10768 |
MNDR | hsa-miR-130a-3p | Burkitt lymphoma | MNDR-E-MI-10769 |
MNDR | hsa-miR-130a-3p | Tonsil cancer | MNDR-E-MI-10770 |
MNDR | hsa-miR-130a-3p | Neuromyelitis optica | MNDR-E-MI-10771 |
MNDR | hsa-miR-130a-3p | Psoriasis | MNDR-E-MI-10772 |
MNDR | hsa-miR-130a-3p | Acute myelocytic leukemia | MNDR-E-MI-10773 |
MNDR | hsa-miR-130a-3p | Colorectal cancer | MNDR-E-MI-10774 |
MNDR | hsa-miR-130a-3p | Nasopharyngeal carcinoma | MNDR-E-MI-10775 |
MNDR | hsa-miR-130a-3p | Nasopharynx carcinoma | MNDR-E-MI-10776 |
MNDR | hsa-miR-130a-3p | Diabetes mellitus | MNDR-E-MI-10777 |
MNDR | hsa-miR-130a-3p | Type 2 diabetes mellitus | MNDR-E-MI-10778 |
MNDR | hsa-miR-130a-3p | Multiple myeloma | MNDR-E-MI-10779 |
MNDR | hsa-miR-130a-3p | Ovarian epithelial cancer | MNDR-E-MI-10780 |
MNDR | hsa-miR-130a-3p | Ependymoma | MNDR-E-MI-10781 |
MNDR | hsa-miR-130a-3p | Nasopharyngeal cancer | MNDR-E-MI-10782 |
MNDR | hsa-miR-130a-3p | Aids dementia complex | MNDR-E-MI-10783 |
MNDR | hsa-miR-130a-3p | Polymyositis | MNDR-E-MI-10784 |
MNDR | hsa-miR-130a-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-10785 |
MNDR | hsa-miR-130a-3p | Gait ataxia | MNDR-E-MI-10786 |
MNDR | hsa-miR-130a-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-10787 |
MNDR | hsa-miR-130a-3p | Stroke lacunar | MNDR-E-MI-10788 |
MNDR | hsa-miR-130a-3p | Non-alcoholic fatty liver disease | MNDR-E-MI-10789 |
MNDR | hsa-miR-130a-3p | Breast cancer her3+ negative | MNDR-E-MI-10790 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ACVR1 | Homo sapiens | RR00038727 |
TOP